The Group made its initial public offering of shares on May 24, 2006, and was traded on the main board of the Hong Kong Stock Exchange Limited on June 6, 2006 (stock code: 474.HK). The Group is a comprehensive investment group. Based on diversified investments, the Group will focus on developing the life science industry in the future, laying out key areas and technologies for the future development of human life science, investing in incubating the world's leading life science companies, and building the world's leading life science research platform. At the same time, leading overseas technologies will be implemented in China and Southeast Asian countries through cooperation and incubation of the acquired exclusive overseas management rights with leading pharmaceutical companies in the Greater China region. The Group creates ideal returns for investors through a diversified and steady business model. Additionally, the Group holds Haotian International Construction Investment Group Co., Ltd. (“Haotian International Construction, 134.HK”). As of March 31, 2020, the total assets of the Group exceeded HK$5 billion.